The physiological responses of somatostatin are mediated by five different G protein-coupled receptors. Although agonist-induced endocytosis of the various somatostatin receptor subtypes (sst 1 -sst 5 ) has been studied in detail, little is known about their postendocytic trafficking. Here we show that somatostatin receptors profoundly differ in patterns of ␤-arrestin mobilization and endosomal sorting. The ␤-arrestin-dependent trafficking of the sst 2A somatostatin receptor resembled that of a class B receptor in that upon receptor activation, ␤-arrestin and the receptor formed stable complexes and internalized together into the same endocytic vesicles. This pattern was dependent on GRK2 (G protein-coupled receptor kinase 2)-mediated phosphorylation of a cluster of phosphate acceptor sites within the cytoplasmic tail of the sst 2A receptor. Unlike other class B receptors, however, the sst 2A receptor was rapidly resensitized and recycled to the plasma membrane. The ␤-arrestin mobilization of the sst 3 and the sst 5 somatostatin receptors resembled that of a class A receptor in that upon receptor activation, ␤-arrestin and the receptor formed relatively unstable complexes that dissociated at or near the plasma membrane. Consequently, ␤-arrestin was excluded from sst 3 -containing vesicles. Unlike other class A receptors, a large proportion of sst 3 receptors was subject to ubiquitin-dependent lysosomal degradation and did not rapidly recycle to the plasma membrane. The sst 4 somatostatin receptor is unique in that it did not exhibit agonist-dependent receptor phosphorylation and ␤-arrestin recruitment. Together, these findings may provide important clues about the regulation of receptor responsiveness during long-term administration of somatostatin analogs.
Somatostatin (SS-14)
1 is an important regulator of neurotransmission in the brain as well as of hormone secretion from the anterior pituitary gland, the pancreas, and the gastrointestinal tract. Five genes encoding six different somatostatin receptor subtypes (sst 1 , sst 2A , sst 2B , sst 3 , sst 4 , sst 5 ) have been cloned. These receptors are widely expressed in the central nervous system and periphery, and multiple somatostatin receptor subtypes often coexist in the same cell (1, 2) . The high density of somatostatin receptors on human neuroendocrine tumors (3) (4) (5) has been used clinically to treat the symptoms of hormonal hypersecretion in patients with growth hormoneand thyrotropin-secreting pituitary adenomas and patients harboring islet cell or carcinoid tumors (6 -8) . Moreover, it has allowed the development of somatostatin receptor scintigraphy for tumor imaging as well as somatostatin receptor-targeted radiotherapy (9, 10) . The fact that naturally occurring somatostatin peptides have only short half-lives has necessitated the development of stable somatostatin peptide analogs including octreotide and lanreotide. Although SS-14 binds with high affinity to all five somatostatin receptors, octreotide and lanreotide bind only to sst 2 with high affinity and to sst 3 and sst 5 with moderate affinity (1, 11) .
It is well known that the physiological responses to SS-14 are diminished with continued exposure (1) . However, important differences have been observed in the response of neuroendocrine tumors to the long-term application of stable somatostatin analogs. In patients harboring somatostatin receptor-expressing growth hormone-secreting adenoma, the inhibitory effects of somatostatin analogs on hormone secretion persist for many years during long-term treatment, and only few thyrotropin-secreting tumors escape from octreotide therapy. In contrast, islet cell tumors and carcinoids are very likely to undergo desensitization within weeks to months of octreotide exposure (12) . Although studies in transfected host cells have examined agonist-induced internalization of the various somatostatin receptor subtypes (2) , the molecular basis for the distinct longterm responsiveness of individual target cells has not been established. So far only species-related differences in agonistmediated endocytosis of somatostatin receptors have been observed, e.g. the rat sst 4 receptor appears to be largely resistant to agonist-induced internalization and desensitization (13) , whereas the human sst 4 receptor has been reported to undergo a very slow but clearly detectable endocytosis. Other studies have shown that the human sst 1 receptor but not the rat sst 1 receptor failed to internalize in an agonist-dependent manner (14, 15) .
The aim of the present study was to characterize early molecular events after agonist activation that lead to functional desensitization and sequestration of the distinct somatostatin receptor subtypes. Moreover, we wanted to delineate the molecular determinants that dictate the differential trafficking and endosomal sorting of somatostatin receptors. All five somatostatin receptors belong to the superfamily of G protein-coupled receptors (GPCRs). After agonist binding and activation of GPCRs, the signaling is turned off by phosphorylation of intracellular receptor domains and subsequent recruitment of cytoplasmic proteins termed arrestins that interrupt coupling between the receptor and its cognate heterotrimeric G protein (16, 17) . ␤-Arrestins also function as docking proteins that link the receptor to components of the endocytic machinery such as AP-2 and clathrin and as scaffolding proteins to turn on signaling to mitogen-activated protein kinase (MAPK) cascades (18) . Within the endosomal compartment, ␤-arrestins regulate the rate at which internalized receptors are dephosphorylated and recycled to the plasma membrane (19, 20) . Based on their binding properties to different isoforms of ␤-arrestin, GPCRs have been categorized into two classes. Class A receptors (e.g. -opioid, ␤ 2 and ␣ 1B adrenergic, endothelin A, and dopamine D1A receptors) do not bind visual arrestin and have a higher affinity for nonvisual ␤-arrestin-2 than ␤-arrestin-1. Class B receptors (e.g. substance P, angiotensin AT 1a , neurotensin 1, and vasopressin 2 receptors) bind visual arrestin and have similar affinities for ␤-arrestin-1 and ␤-arrestin-2 (16). Class A and class B receptors also differ in the fate of the ␤-arrestinreceptor complex. For class A receptors, ␤-arrestin directs the receptors to clathrin-coated pits but does not internalize with them. For class B receptors, ␤-arrestin forms stable complexes with the receptors, such that the receptor-␤-arrestin complex internalizes as a unit into early endosomes (17) .
Here we identify the sst 3 and sst 5 somatostatin receptors as class A receptors and the sst 2A somatostatin receptor as class B receptor. The trafficking of the sst 1 and sst 4 somatostatin receptors did not appear to depend on ␤-arrestins. We demonstrate that the formation of stable complexes between ␤-arrestin and sst 2A requires G protein-coupled receptor kinase 2 (GRK2)-mediated phosphorylation of a cluster of phosphate acceptor sites within the cytoplasmic tail of the sst 2A receptor. We also show that sst 2A and sst 3 underwent differential endosomal sorting. In contrast to what would be expected from their ␤-arrestin mobilization patterns, the sst 2A receptor was rapidly recycled to the plasma membrane whereas the sst 3 receptor was subject to ubiquitination-dependent lysosomal degradation.
EXPERIMENTAL PROCEDURES
Materials-Monoclonal mouse anti-ubiquitin antibody (UbP4D1) was from Santa Cruz Biotechnology. Mouse monoclonal anti-T7 antibody and mouse monoclonal anti-T7 antibody covalently coupled to Sepharose beads were obtained from Novagen (Madison, WI). The rabbit anti-sst 2A antibody was generated to the peptide ETQRTLLNG-DLQTSI, which corresponds to residues 355-369 of the carboxyl-terminal tail of rat/mouse/human sst 2A . The anti-sst 3 antibody was generated to the peptide TAGDKASTLSHL, which corresponds to residues 417-428 of the carboxyl-terminal tail of the rat/mouse sst 3 . Both antibodies have been characterized extensively (21) . All polyclonal rabbit antisera were purified by affinity chromatography using the Sulfo-Link coupling gel coupled to the appropriate immunizing peptide according to the instructions of the manufacturer (Pierce) . Plasmid constructs of the rat sst 1 , sst 2A , sst 3 , sst 4 , and sst 5 containing the amino-terminal T7 epitope tag sequence MASMTGGQQMG in pcDNA3 have been described previously (13, 15, 21) . Truncated sst 2A mutants were created by PCR using primers that introduce stop codons at suitable positions (22) . Point mutations were introduced into sst 2A by PCR replacing threonine 353, 355, and 356 with alanine. The sequences of all constructs were verified by dideoxynucleotide sequencing. The plasmid encoding ␤-arrestin-1-enhanced green fluorescence protein (EGFP) was kindly provided by N. W. Bunnett (University of California, San Francisco). The construct encoding the ␤-arrestin-2-EGFP fusion protein was obtained from Biosignal (Montreal, Canada). Transferrin-Alexa Fluor 488 was purchased from Molecular Probes (Leiden, The Netherlands).
Cell Culture and Transfection-Human embryonic kidney (HEK) 293 cells were obtained from ATCC and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum in a humidified atmosphere containing 10% CO 2 . Transfections were performed using LipofectAMINE 2000 according to the instructions of the manufacturer (Invitrogen). Stable transfectants were selected in the presence of 500 g/ml G418 (Invitrogen). HEK 293 cells stably expressing the T7-tagged sst 2A (B max , 820 Ϯ 19 fmol/mg membrane protein) or T7-tagged sst 3 receptors (B max , 1,182 Ϯ 31 fmol/mg membrane protein) were characterized using radioligand binding assays, Western blot analysis, and immunocytochemistry as described previously (21) . The level of somatostatin receptor expression was between 1,500 and 2,000 fmol/mg membrane protein for all experiments using transiently transfected HEK 293 cells.
Confocal Microscopy-One day after transfection, cells were seeded into 35-mm glass-bottom culture dishes (Mattek, Ashland, MA). The next day, cells were incubated for 2 h in serum-free OPTIMEM-1 medium (Invitrogen) containing 10 mM Hepes (pH 7.4). Cells were then transferred onto a temperature-controlled microscope stage set at 37°C. Confocal microscopy was performed using a Leica TCS NT laser scanning confocal microscope (Heidelberg, Germany). Analysis of ␤-arrestin translocation was performed in cells transiently cotransfected with 1.5 g of either ␤-arrestin-1-EGFP or ␤-arrestin-2-EGFP and 6 g of the various somatostatin receptor subtypes. When indicated, 4 g of GRK2 or 4 g of empty vector (MOCK) were included in the transfections. Images were collected sequentially using single line excitation at 488 nm with 515-540-nm band pass emission filters. Saturating concentrations of SS-14 (1 M) were applied directly into the culture medium immediately after the initial image was taken.
Immunocytochemistry-Cells were grown on poly-L-lysine-coated coverslips overnight. After the appropriate treatment with SS-14, cells were fixed with 4% paraformaldehyde and 0.2% picric acid in phosphate buffer (pH 6.9) for 40 min at room temperature and washed several times in TPBS (10 mM Tris-HCl, pH 7.4, 10 mM phosphate buffer, 137 mM NaCl, and 0.05% thimerosal). Specimens were then incubated for 3 min in 50% methanol and 3 min in 100% methanol, washed in TPBS, and preincubated with TPBS supplemented with 3% normal goat serum for 1 h at room temperature. Cells were then incubated with affinitypurified anti-T7, anti-sst 2A , or anti-sst 3 antibodies at a concentration of 1 g/ml in TPBS supplemented with 1% normal goat serum overnight. After washing with TPBS, bound primary antibody was detected with cyanine 3.18-conjugated secondary antibody (Jackson Immunoresearch, West Grove, PA). Cells were then dehydrated, cleared in xylol, and permanently mounted in DPX (Fluka, Deisenhofen, Germany). For ␤-arrestin-2-EGFP/sst 2A colocalization studies, cells were mounted directly in Vectashield Hard Set mounting medium (Vector, Burlingame, CA). Specimens were examined using a Leica TCS NT laser scanning microscope. Cyanine 3.18 was imaged with 568 nm excitation and 570 -630-nm band pass emission filters.
Transferrin Trafficking-A previously described pulse-chase assay was used to estimate the degree to which a "pulse" of internalized sst 2A or sst 3 was accessible to a subsequent "chase" of endocytosed transferrin (23) . HEK 293 cells stably expressing T7-tagged sst 2A or sst 3 were grown on glass coverslips, and receptors were surface-labeled with 1 g/ml T7 antibody. In the first set of experiments, cells were simultaneously incubated with 1 M SS-14 and 5 g/ml Alexa Fluor 488-conjugated transferrin for 30 min at 37°C. In a second set of experiments, cells were first incubated with 1 M SS-14 for 30 min at 37°C to drive endocytosis of antibody-labeled receptors. Next, cells were chilled on ice, rinsed with EDTA-supplemented phosphate-buffered saline, rewarmed for 20 min in medium lacking agonist but containing 5 g/ml Alexa Fluor 488-conjugated transferrin. Cells were fixed and permeabilized, and antibody-labeled sst 2A or sst 3 receptors were detected using cyanine 3.18-conjugated secondary antibodies. Specimens were examined as described above.
Whole Cell Phosphorylation Assay-HEK 293 cells were plated at a density of 10 6 cells/dish onto 100-mm dishes. The next day, cells were transfected with the appropriate plasmids. Two days later, cells were washed with serum-and phosphate-free medium and then labeled with 200 Ci/ml carrier-free 32 P-orthophosphate (285 Ci/mg P i , ICN, Eschwege, Germany) for 60 min at 37°C. Labeled cells were then exposed to 1 M SS-14 for 20 min. Subsequently, cells were placed on ice and washed with ice-cold phosphate-buffered saline. Cells were then scraped into 1 ml of radioimmune precipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 10 mM disodium pyrophosphate, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.2 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 1 g/ml pepstatin A, 1 g/ml aprotinin, and 10 g/ml bacitracin). Cells were solubilized on a rotating platform for 60 min at 4°C. After centrifugation at 30,000 ϫ g for 60 min at 4°C, receptor proteins were immunoprecipitated using T7 affinity beads. Receptors were eluted from the beads using SDS-sample buffer for 20 min at 60°C. The samples were subjected to 8% SDS-PAGE followed by autoradiography. The extent of receptor phosphorylation was quantitated using a Fuji phosphoimaging system and BAS 1000 software. Loading of equal amounts of receptor proteins in each lane was confirmed by Western blot analysis. Receptor phosphorylation was expressed as a percent of wild-type sst 2A . Means Ϯ S.E. of three independent experiments are reported.
Western Blot Analysis-Stably transfected HEK 293 cells were plated onto poly-L-lysine-coated 100-mm dishes and grown to 80% confluence. After treatment with SS-14 in serum-free medium, cells were lysed in radioimmune precipitation buffer as described above. Glycosylated proteins were partially enriched using wheat germ-lectin-agarose beads (Amersham Biosciences). Proteins were eluted from the beads using SDS-sample buffer for 20 min at 60°C and then resolved on 8% SDS-polyacrylamide gels. After electroblotting, the membranes were incubated with 1 g/ml anti-sst 2A or anti-sst 3 antibody for 12 h at 4°C followed by detection using an enhanced chemiluminescence detection system (Amersham Biosciences). For ubiquitination studies, 200 M chloroquine (Sigma) and 25 M MG132 (Calbiochem) were added to the culture medium 30 min before and during agonist treatment. Cells were then lysed in radioimmune precipitation buffer containing 200 M chloroquine, 25 M MG132, and 10 mM N-ethylmaleimide (Calbiochem). Receptor proteins were precipitated with T7 affinity beads. Ubiquitinated receptors were detected using anti-ubiquitin antibodies (2 g/ml).
NIH Image 1.62 software was used to desensitize and quantify protein bands detected on Western blots. Statistical analysis was carried out with the Student's t test using GraphPad Prism 3.0 software. p-values of Ͻ0.05 were considered statistically significant.
RESULTS
Differential ␤-Arrestin Mobilization of Somatostatin Receptors-We employed functional ␤-arrestin-1 and ␤-arrestin-2 conjugated to enhanced green fluorescent protein to visualize the translocation of ␤-arrestins to the plasma membrane in live HEK 293 cells transfected with distinct somatostatin receptor subtypes. In the absence of the agonist, both ␤-arrestin-EGFP isoforms were uniformly distributed throughout the cytoplasm of the cells (Fig. 1, 0 min) . ␤-Arrestin-1 was also detectable inside the cell nucleus. The addition of saturating concentrations of SS-14 induced a rapid redistribution of ␤-arrestin-1 as well as ␤-arrestin-2 from the cytoplasm to the plasma membrane in sst 2A -and sst 3 -transfected cells. In sst 3 -expressing cells, fluorescence outlining the shape of the cells was less marked in cells cotransfected with ␤-arrestin-1 as compared with cells cotransfected with ␤-arrestin-2. In sst 5 -transfected cells, only translocation of ␤-arrestin-2 but not ␤-arrestin-1 was observed. Translocation of ␤-arrestin-1 or ␤-arrestin-2 to the plasma membrane was not detectable in cells transfected with either sst 1 or sst 4 . After extended agonist exposure, internalization of ␤-arrestin-EGFP into endocytotic vesicles was observed only in sst 2A -expressing cells (Fig. 1, 50 min) . Dual color confocal microscopy revealed that ␤-arrestin-2-EGFP and sst 2A were extensively colocalized in early endosomes (Fig. 2) . In both sst 3 -and sst 5 -expressing cells, ␤-arrestin-EGFP ultimately redistributed to the cytoplasm after prolonged SS-14 exposure (Fig. 1, 50 min) .
Agonist-induced Receptor Phosphorylation and ␤-Arrestin Trafficking-Formation of stable complexes between ␤-arrestin and GPCRs strongly depends on the presence of clusters of phosphate acceptor sites (defined as serine/threonine residues occupying three consecutive positions or three of four positions) within the carboxyl-terminal tail of the receptor (16, 17) . These clusters are remarkably conserved in their position within the carboxyl-terminal domain and serve as primary sites of agonistdependent receptor phosphorylation. The carboxyl-terminal tails of the sst 2A , sst 3 , and sst 4 receptors contain such clusters of phosphate acceptor sites; however, they occupy different positions with regard to the conserved NPILY motif, which marks the end of the seventh transmembrane domain and the beginning of the cytoplasmic tail (Fig. 3A) . To delineate a mechanistic basis for the observed differences in the trafficking patterns of these three receptors, we assessed whole cell receptor phosphorylation and ␤-arrestin-dependent trafficking in the presence and absence of GRK2. Overexpression of GRK2 promoted a marked increase in SS-14-dependent phosphorylation of the sst 2A receptor (Fig. 3C, left panel) and facilitated the recruitment of ␤-arrestin-2 to the plasma membrane as well as its trafficking with the receptor into the endocytotic vesicles (Fig. 3B, upper panel) , indicating that these processes strongly depend on the cellular complement of GRK2. In sst 3 -expressing cells, agonist-induced receptor phosphorylation (Fig. 3C , middle panel) and ␤-arrestin-2 trafficking (Fig. 3B, lower panel) were largely independent of the presence of overexpressed GRK2. Although the sst 4 receptor contains several putative phosphorylation sites in its cytoplasmic tail (Fig. 3A) , we were not able to detect any agonist-induced receptor phosphorylation (Fig. 3C, right panel) or ␤-arrestin-2 mobilization (not shown) in the presence or absence of GRK2.
Molecular Determinants Underlying the Cotrafficking of ␤-Arrestin and sst 2A into Endocytotic Vesicles-To determine the sites required for GRK2-mediated phosphorylation and ␤-arrestin mobilization of the sst 2A receptor, serial truncations were constructed deleting either 10 (359X), 15 (354X), or 20 (349X) amino acids of its carboxyl-terminal tail (Fig. 4A) . As depicted in Fig. 4 , B and C, deletion of 10 amino acids of the sst 2A receptor tail (359X mutant), which contain serine-368 and threonine-367 as potential phosphorylation sites, reduced GRK2-mediated phosphorylation by ϳ10% (residual phosphorylation, 89% Ϯ 4%; n ϭ 3) (Fig. 4C) . Analysis of ␤-arrestin mobilization of the 359X mutant revealed that the receptor is still phosphorylated sufficiently enough to induce a translocation of ␤-arrestin-2-EGFP to the plasma membrane (Fig. 4B) . However, analysis of the 359X receptor also showed that phosphorylation of serine 368 and/or threonine 367 is required for formation of stable ␤-arrestin-sst 2A complexes (Fig. 4B) . Deletion of 15 amino acids of the sst 2A receptor tail (354X mutant), which contain two more potential phosphorylation sites, namely threonine 359 and threonine 356, reduced GRK2-mediated phosphorylation by ϳ40% (residual phosphorylation, 62% Ϯ 14%; n ϭ 3) (Fig. 4C) . Analysis of ␤-arrestin trafficking of the 356X mutant revealed that the residual receptor phosphorylation was not sufficient to induce translocation of ␤-arrestin-2-EGFP to the plasma membrane (Fig. 4B) . Deletion of 20 amino acids of the sst 2A receptor tail (349X mutant), which contain two additional potential phosphorylation sites, namely threonine 354 and threonine 353, strongly reduced GRK2-mediated phosphorylation (residual phosphorylation, 19% Ϯ 4%; n ϭ 3) and ␤-arrestin binding (Fig. 4, B and C) . In the AAEA mutant, the cluster of threonine 353, 355, and 356 was replaced by alanine residues. The level of agonist-induced phosphorylation was reduced by 55% as compared with the wild-type sst 2A (residual phosphorylation, 44% Ϯ 2%; n ϭ 3) (Fig. 4C) . In cells expressing the AAEA mutant, agonist-induced ␤-arrestin-2 translocation was strongly inhibited, and fluorescence outlining the cell shape was hardly detectable. Immunocytochemical staining of nonpermeabilized cells using anti-T7 antibodies revealed that all sst 2A mutants were targeted to the plasma membrane (not shown). These data suggest that many if not all of the potential phosphate acceptor sites contained within the 20 carboxyl-terminal amino acids are involved in GRK2-mediated phosphorylation of the sst 2A receptor and that phosphorylation of these sites is required for formation of stable ␤-arrestin-sst 2A complexes. These data also suggest that the cluster of threonine 353, 355, and 356 may represent the primary site for GRK2-mediated phosphorylation and ␤-arrestin binding.
Fate of sst 2A and sst 3 after Agonist-induced InternalizationThe pattern of ␤-arrestin trafficking is believed to dictate the rate of receptor recycling and resensitization. In fact, many class A receptors have been shown to recycle rapidly, whereas class B receptor-like trafficking patterns are often observed for slowly recycling receptors. We therefore examined the redistribution of sst 2A and sst 3 after agonist-induced internalization. Cells were treated for 30 min with SS-14, washed extensively, and subjected to an additional incubation in the absence of agonist for 10, 20, or 40 min. As depicted in Fig. 5 , sst 2A and sst 3 were almost exclusively confined to the plasma membrane in untreated cells. After 30 min of SS-14 exposure, both receptors were extensively sequestered into intracellular vesicles. In the absence of agonist it became apparent that nearly the entire pool of internalized sst 2A receptors recycled to the plasma membrane during the 40-min SS-14-free interval. In   FIG. 3 . Agonist-induced receptor phosphorylation and ␤-arrestin mobilization. A, carboxyl-terminal amino acid sequences of sst 2A , sst 3 , and sst 4 are depicted beginning with the conserved NPILY motif, which marks the end of the seventh transmembrane domain and the beginning of the cytoplasmic tail. Potential phosphate acceptor sites are underlined. B, HEK 293 cells were transiently transfected with 1.5 g of ␤-arrestin-2-EGFP, 6 g of sst 2A , or 6 g of sst 3 and either 4 g of GRK2 or 4 g of empty vector. The distribution of ␤-arrestin was visualized sequentially in the same live cells before (0 min) and after (3, 5, 10 , and 30 min) the addition of SS-14 to the culture medium. Receptor expression levels were between 1,500 and 2,000 fmol/mg membrane protein. Shown are representative images from one of three independent experiments performed in duplicate. Arrowheads, translocation of ␤-arrestin-2-EGFP to the plasma membrane; arrows, trafficking of ␤-arrestin-2-EGFP into early endosomes. Scale bar, 20 m. C, HEK 293 cells were transfected with sst 2A , sst 3 , or sst 4 and either GRK2 or empty vector. Two days later, cells were either not exposed or exposed to 1 M SS-14 for 20 min, and whole cell receptor phosphorylation was determined as described under "Experimental Procedures." Upper panel, autoradiographs from representative experiments are shown. Lower panel, aliquots of the immunoprecipitates (IP) were immunoblotted with T7 antibody (IB, immunoblot) to confirm equal loading of the gels. Two additional experiments gave similar results. Note that overexpression of GRK2 strongly increased agonist-induced phosphorylation of sst 2A (179 Ϯ 25%, p Ͻ 0.05) compared with agonist-induced phosphorylation in the absence of overexpressed GRK2, whereas agonist-induced phosphorylation of sst 3 (113 Ϯ 18%) was not significantly increased in the presence of overexpressed GRK2. The position of molecular mass markers are indicated on the left (in kDa).
contrast, only part of the internalized sst 3 receptors were redistributed to the plasma membrane, whereas a large proportion of sst 3 receptors was sequestered into intracellular clusters of relatively large vesicles (Fig. 5, 20 and 40 min) . To examine whether sst 2A and sst 3 receptors were internalized into the same pool of endosomes, we used an immunocytochemical pulse-chase assay to estimate the degree to which internalized sst 2A or sst 3 receptors remain associated with endocytic vesicles that can be labeled with Alexa Fluor 488-labeled transferrin, a well established marker of early and recycling endosomes that mediate rapid recycling (23) . T7-tagged sst 2A and sst 3 receptors present in the plasma membrane were specifically labeled by incubating intact cells with antibody. When these cells were simultaneously incubated with SS-14 and Alexa Fluor 488-conjugated transferrin for 30 min, a high degree of colocalization of both sst 2A and sst 3 with transferrin was observed, confirming that these receptors were internalized via the same endocytic pathway (Fig. 6, left panel; colocalization is indicated by the numerous yellow structures observed in the overlay panels (bottom row)). However, when these cells were first incubated with SS-14 to initiate a 30-min pulse of endocytosis and then chased for an additional 20 min in the presence of labeled transferrin, the extent of colocalization between the pulse of internalized sst 2A or sst 3 and the endocytic tracer was dramatically different (Fig. 6, right panel) . Most vesicles containing internalized sst 2A colocalized with endocytosed transferrin, which is consistent with rapid recycling of internalized sst 2A via early and recycling endosomes. In contrast, under the same conditions, sst 3 was observed in a large number of endocytic vesicles that did not contain detectable transferrin. These observations support the idea that the failure of internalized sst 3 to recycle rapidly is mediated, at least in part, by sorting of internalized receptors to a population of endocytic vesicles distinct from those that constitute the conserved recycling pathway marked by transferrin.
Differential Down-regulation of sst 2A and sst 3 -Given the differential intracellular trafficking of sst 2A and sst 3 , we next assessed the down-regulation of these receptors during prolonged SS-14 exposure by Western blot analysis. As shown in Fig. 7A , we did not observe any detectable change in the level of cellular sst 2A receptors during the 16-h treatment period. In contrast, the sst 3 receptor underwent pronounced down-regulation, which became clearly detectable after 3 h of agonist exposure (65 Ϯ 9% of untreated control) (Fig. 7B) . The degradation of sst 3 was blocked completely by the lysosomal inhibitor chloroquine (Fig. 7C) . Surprisingly, the degradation of sst 3 was also blocked by the proteasomal inhibitor MG132 (Fig. 7C) . Although MG132 is a highly potent inhibitor of a number of proteasome-associated proteases, this compound is not specific for proteasomes and also potently inhibits various cysteine proteases and cathepsins (25) . These results suggest that sst 2A and sst 3 undergo differential endosomal sorting. Although sst 2A was sequestered into the endosomal recycling compartment, a huge proportion of endocytosed sst 3 receptors was sorted into the degradative lysosomal pathway. To establish a molecular basis for the differential endosomal sorting of the sst 2A and the sst 3 receptors, we examined the agonist-dependent ubiquitination of these receptors. Cells were exposed to SS-14, receptor proteins were immunoprecipitated, and ubiquitinated receptors were detected using an anti-ubiquitin monoclonal antibody. As depicted in Fig. 8 , the sst 3 receptor underwent time-dependent ubiquitination, which was apparent as a broad high molecular weight band that represents the receptor linked to multiple ubiquitin monomers. In contrast, SS-14 treatment of sst 2A -expressing cells did not result in any detectable change in sst 2A receptor ubiquitination.
DISCUSSION
In the present study, we reveal previously unappreciated differences in ␤-arrestin mobilization and endosomal sorting of the five somatostatin receptor subtypes. Based on their ␤-arrestin-dependent trafficking patterns, we identify the sst 3 appear to depend on ␤-arrestins. We also show that sst 2A and sst 3 underwent differential endosomal sorting. In contrast to what would be expected from their ␤-arrestin trafficking patterns, the sst 2A receptor was rapidly recycled to the plasma membrane, whereas the sst 3 receptor was subject to ubiquitination-dependent lysosomal degradation.
Using a series of truncated sst 2A receptors, we demonstrate that the molecular determinants for the formation of stable complexes between ␤-arrestin and sst 2A are contained within clusters of phosphate acceptor sites at the end of its cytoplasmic tail. Such clusters of phosphate acceptor sites are defined as serine/threonine residues occupying three consecutive positions or three of four positions (17) . For many class B receptors, these clusters are remarkably conserved in their position within the carboxyl-terminal domain and serve as primary sites of agonist-dependent receptor phosphorylation. It should be noted that not only the sst 2A receptor but also the sst 3 and sst 4 receptors contain such clusters of phosphate acceptor sites. However, with regard to the conserved NPILY motif these clusters occupy more downstream positions in the sst 3 and sst 4 receptors than in the sst 2A receptor. We also demonstrate that the phosphorylation of the sst 2A receptor but not of the sst 3 and sst 4 receptors strongly depends on the cellular complement of GRK2.
The sst 3 receptor formed complexes with ␤-arrestin that dissociated at or near the plasma membrane. Neither ␤-arrestin mobilization nor phosphorylation of the sst 3 receptor was changed by overexpression of GRK2. Interestingly, it has previously been shown that replacement of four serine and threonine residues by alanine diminishes agonist-induced phosphorylation and internalization of the sst 3 receptor (24) . Consistent with the present findings, these residues are localized upstream to the putative GRK2 phosphorylation cluster of sst 3 .
In contrast to the sst 2A and sst 3 receptors, the sst 1 and sst 4 receptors failed to induce ␤-arrestin translocation to the plasma membrane following agonist treatment. These results imply either peculiar mechanisms of receptor desensitization or resistance to desensitization. In fact, it has previously been shown that the rat sst 4 receptor fails to internalize after agonist activation (13) . Consistent with the previous findings, we show that sst 4 did not undergo any detectable phosphorylation after agonist activation despite the presence of a number of potential phosphate acceptor sites including a cluster of thre- 3 was used to examine colocalization between a 30-min agonist pulse of antibody-labeled receptors (red) followed by a 20-min chase with transferrin (green) in the absence of SS-14 as described under "Experimental Procedures." The majority of vesicles containing internalized sst 2A also contained detectable labeled transferrin. In contrast, in the same experiment conducted using sst 3 -expressing cells, we observed numerous sst 3 -enriched vesicles that contained no detectable labeled transferrin (arrows). Shown are representative images from one of three independent experiments performed in duplicate. Scale bar, 15 m.
onine residues occupying four of five positions in its carboxylterminal tail (13) . In addition, we demonstrate that the sst 4 receptor was resistant to agonist-induced phosphorylation and ␤-arrestin-dependent trafficking even in the presence of GRK2. With regard to the sst 1 receptor it should be noted that upon heterologous expression in HEK 293 cells, a large proportion of receptor protein remains in an as yet unidentified intracellular vesicular compartment (4) . Thus, the fact that only a fraction of cellular sst 1 receptors is targeted to the plasma membrane may explain that agonist exposure of this receptor did not promote efficient ␤-arrestin translocation under these conditions.
In sst 5 -transfected HEK 293 cells, SS-14 treatment induced ␤-arrestin translocation to the plasma membrane. However, this effect was only transient and less pronounced than that observed for the sst 2A and sst 3 receptors. Given that sst 5 has a higher affinity for SS-28 than for SS-14, the limited recruitment of ␤-arrestin-2 could be because of limited activation of the sst 5 receptor by SS-14 (26) . We therefore performed ␤-arrestin mobilization assays using the non-peptide sst 5 agonist L-817,818. The fact that very similar results were obtained under these conditions confirms that the sst 5 receptor exhibits a class A receptor-like trafficking pattern.
It has been suggested recently that distinct intracellular trafficking patterns of ␤-arrestin determine the fate of internalized GPCRs (19, 20) . Many class A receptors (e.g. -opioid, ␤ 2 and ␣ 1B adrenergic, endothelin A, and dopamine D1A receptors) have been shown to recycle rapidly, whereas class B receptor-like trafficking patterns are often observed for slowly recycling receptors (e.g. substance P, angiotensin AT 1a , neurotensin-1, and vasopressin-2 receptors) (20) . However, recent work shows that not all GPCRs fit into this classification, i.e. the N-formyl peptide receptor requires ␤-arrestin for its recycling but not for its internalization (27) . Here, we show the sst 2A receptor was rapidly recycled to the plasma membrane without any detectable loss of cellular sst 2A receptors even during prolonged agonist exposure. In contrast, a large proportion of internalized sst 3 receptors was ubiquitinated and sorted into the degradative lysosomal pathway, resulting in a rapid down-regulation of cellular sst 3 receptors. Thus, our findings suggest that endosomal sorting of sst 2A and sst 3 was regulated by differential ubiquitination rather than differential ␤-arrestin binding of these receptors.
In conclusion, we provide evidence for differential ␤-arrestindependent trafficking and endosomal sorting of somatostatin receptor subtypes. The high density of somatostatin receptors on human neuroendocrine tumors has allowed the development of somatostatin receptor scintigraphy for tumor imaging as well as somatostatin receptor-targeted radiotherapy (9, 10) . The effectiveness of these diagnostic and therapeutic manipulations strongly depends on receptor internalization and recycling. Thus, a sst 2A -expressing tumor would be expected to take up radiolabeled somatostatin analogs more efficiently than tumors that express predominantly sst 3 or sst 4 . In addition, differences have been observed in the response of neuroendocrine tumors to long-term application of stable somatostatin analogs. In patients with growth hormone-secreting pituitary adenoma, the inhibitory effects of somatostatin analogs on hormone secretion persist for many years during long-term treatment. In contrast, carcinoids are very likely to undergo desensitization within weeks to months of octreotide exposure. Although sst 2A is most frequently detected, neuroendocrine tumors often express distinct patterns of somatostatin receptor subtypes (3). Thus, the differential intracellular sorting of somatostatin receptors may provide important clues about the regulation of receptor responsiveness during long-term administration of somatostatin analogs. Cells were lysed, and the receptors were precipitated using T7 affinity beads and Western-blotted using anti-ubiquitin antibodies as described under "Experimental Procedures." Two additional experiments gave similar results. The position of molecular mass markers is indicated on the left (in kDa).
